BMYBristol-Myers SquibbFinished
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Multiple Myeloma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 67 (final count)
- Started
- Jul 15, 2016
- Main results expected
- Feb 23, 2026
- Fully finished
- Feb 23, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The number of participants who received at least one dose of elotuzumab or backbone therapy (other study drugs) and the duration of treatment will be collected.
Measured over: Maximum duration is until all participants have discontinued study drugs, or until all participants are treated for up to 2 years, unless BMS chooses to extend the study.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02719613 · record last updated 2026-04-15 · checked 2026-11-09 15:47 UTC